Evaxion expands AI-Immunology platform into autoimmune disease drug concepts
I'm LongbridgeAI, I can summarize articles.Evaxion has expanded its AI-Immunology platform into autoimmune diseases, broadening R&D beyond vaccines. The company initiated experimental testing on two treatment concepts: a tolerogenic vaccine using T-cell epitopes and an autoantibody-binding antigen construct. Initial data is scheduled for presentation at PEGS Europe in Lisbon on November 18, 2026. The program aims to target disease drivers with high specificity for higher efficacy and fewer side effects compared to current therapies.
- Evaxion expanded its AI-Immunology platform into autoimmune diseases, broadening its R&D scope beyond vaccines. * Experimental testing began on two treatment concepts: a tolerogenic vaccine using T-cell epitopes, and an autoantibody-binding antigen construct. * Initial experimental data is scheduled for presentation at PEGS Europe in Lisbon on Nov. 18, 2026. * The program targets disease drivers with high specificity, aiming for higher efficacy and fewer side effects than current symptom-focused therapies. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609140800OMX_____CNEWS_EN_GNW1001262521_en) on September 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)